良性前列腺增生患者行钬激光前列腺剜除术(HoLEP)术中出血的影响因素:一项大型多中心分析
该多中心分析纳入3个中心963例接受HoLEP的良性前列腺增生患者,评估围手术期出血情况及其影响因素。结果显示HoLEP对出血影响小,抗血栓治疗组与未抗血栓组血红蛋白和血细胞比容下降无显著差异,但抗血栓组输血率更高;手术时间可能影响血红蛋白下降。
要点
- HoLEP对出血影响小,围手术期输血率为5%。
- 抗血栓治疗组与未抗血栓组血红蛋白和血细胞比容下降无显著差异。
- 抗血栓治疗组输血率更高;手术时间可能影响血红蛋白下降。
核心结论
- HoLEP是安全的,对出血无显著影响。
- 接受抗血栓治疗的高危患者出血结局与其余患者相同,但输血率更高。
- 手术时间可能影响血红蛋白下降,对于出血风险较高的患者应考虑手术时间。
研究设计与样本
- 分析3个中心接受HoLEP治疗的良性前列腺增生患者。
- 术前和出院时测量血红蛋白和血细胞比容,记录术中及术后输血情况。
- 分析抗血栓治疗(抗血小板/抗凝)及BPH和其他疾病药物治疗对出血结局的影响。
- 共纳入963例患者,平均年龄72岁。
主要发现
- 前列腺平均(范围)大小102(40-316)g;28%患者接受抗血小板治疗,11%接受抗凝治疗。
- 前列腺特异性抗原平均(范围)6.0(0.3-43.5)ng/dL;手术时间平均(范围)77(28-178)分钟。
- 膀胱结石见于54例(5.6%)患者,均经膀胱碎石术成功治疗。
- 48例(5%)患者在HoLEP术中或术后即刻需要输血。
- 总体平均(标准差)血红蛋白从14.6(1.5)g/dL降至12.3(2.1)g/dL(P <.001),平均(标准差)血细胞比容从44.3%(4.7)降至37.7%(6.5)(P <.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess blood loss during holmium laser enucleation of the prostate (HoLEP) and investigate the factors influencing it. PATIENTS AND METHODS: Analysis of patients with benign prostatic hyperplasia (BPH) treated with HoLEP at 3 centers. Hemoglobin and hematocrit were measured before surgery and hospital discharge. All blood transfusions performed during and after HoLEP were recorded. Blood loss outcomes were analyzed regarding antithrombotic (antiplatelet/anticoagulant) therapies and drug treatments for BPH and other conditions. RESULTS: The analysis included 963 patients with a mean age of 72 years. Mean (range) prostate size was 102 (40-316) g; 28% of patients were receiving antiplatelets and 11% anticoagulants. Mean (range) prostate-specific antigen was 6.0 (0.3-43.5) ng/dL. Mean (range) operation time was 77 (28-178) minutes. Bladder calculi were found in 54 (5.6%) patients; all of them were successfully treated with cystolitholapaxy. Forty-eight (5%) patients required blood transfusion during or immediately after the HoLEP procedure. Overall, mean (SD) hemoglobin decreased from 14.6 (1.5) g/dL to 12.3 (2.1) g/dL (P <.001), and mean (SD) hematocrit decreased from 44.3% (4.7) to 37.7% (6.5) (P <.001). Neither hemoglobin nor hematocrit decreases were significantly different between patients receiving and not receiving antithrombotic therapy or BPH therapy. CONCLUSION: HoLEP is safe and has no remarkable impact on blood loss. Patients at high risk, such as those receiving antithrombotic therapy, had the same outcome than the rest regarding blood loss, although showed a higher transfusion rate. Operating time may influence hemoglobin decrease; therefore, it should be considered in patients with higher risk of bleeding.
引用
- Romero-Otero J, García-González L, García-Gómez B, et al. Factors Influencing Intraoperative Blood Loss in Patients Undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia: A Large Multicenter Analysis. Urology. 2019. PMID: 31252004. doi:10.1016/j.urology.2019.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。